TimesSquare Capital Management LLC lifted its holdings in shares of Amedisys Inc (NASDAQ:AMED) by 15.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 731,670 shares of the health services provider’s stock after buying an additional 99,380 shares during the quarter. TimesSquare Capital Management LLC owned about 2.16% of Amedisys worth $45,956,000 at the end of the most recent quarter.
Several other hedge funds have also made changes to their positions in the stock. Federated Investors Inc. PA lifted its stake in Amedisys by 2.3% in the 2nd quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock worth $122,000 after purchasing an additional 44 shares in the last quarter. Ameritas Investment Partners Inc. purchased a new stake in Amedisys in the 1st quarter worth approximately $123,000. State of Alaska Department of Revenue lifted its stake in Amedisys by 2.3% in the 1st quarter. State of Alaska Department of Revenue now owns 3,080 shares of the health services provider’s stock worth $157,000 after purchasing an additional 70 shares in the last quarter. CIBC Asset Management Inc purchased a new stake in Amedisys in the 2nd quarter worth approximately $230,000. Finally, SG Americas Securities LLC lifted its stake in Amedisys by 48.7% in the 2nd quarter. SG Americas Securities LLC now owns 3,743 shares of the health services provider’s stock worth $235,000 after purchasing an additional 1,226 shares in the last quarter. Institutional investors own 96.80% of the company’s stock.
In other Amedisys news, insider David B. Pearce sold 1,000 shares of the business’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $50.00, for a total transaction of $50,000.00. Following the transaction, the insider now owns 10,488 shares in the company, valued at $524,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bruce D. Perkins acquired 2,000 shares of the business’s stock in a transaction on Thursday, August 3rd. The shares were purchased at an average price of $46.60 per share, for a total transaction of $93,200.00. Following the transaction, the director now directly owns 15,825 shares of the company’s stock, valued at $737,445. The disclosure for this purchase can be found here. Insiders own 2.80% of the company’s stock.
A number of brokerages have recently commented on AMED. Mizuho lowered shares of Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 price target on the stock. in a report on Wednesday, July 26th. Bank of America Corporation began coverage on shares of Amedisys in a report on Monday, August 21st. They issued a “neutral” rating and a $55.00 price target on the stock. BidaskClub raised shares of Amedisys from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Finally, Royal Bank Of Canada reissued a “hold” rating and issued a $56.00 price target on shares of Amedisys in a report on Monday, June 5th. Seven equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Amedisys presently has a consensus rating of “Hold” and an average target price of $56.33.
Amedisys Inc (AMED) opened at 51.85 on Friday. The company’s 50 day moving average is $50.35 and its 200 day moving average is $54.72. The company has a market cap of $1.76 billion, a price-to-earnings ratio of 44.32 and a beta of 0.84. Amedisys Inc has a 12-month low of $34.58 and a 12-month high of $65.91.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.12. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. The company had revenue of $378.80 million for the quarter, compared to analysts’ expectations of $380.80 million. During the same quarter in the previous year, the business posted $0.42 earnings per share. Amedisys’s quarterly revenue was up 5.0% on a year-over-year basis. Analysts forecast that Amedisys Inc will post $2.21 earnings per share for the current fiscal year.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.